HHLA2 and TMIGD2: new immunotherapeutic targets of the B7 and CD28 families

Murali Janakiram, Jordan M. Chinai, Aimin Zhao, Joseph A. Sparano, Xingxing Zang

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

We and others recently discovered HHLA2 as a new B7 family member and transmembrane and immunoglobulin domain containing 2 (TMIGD2) as one of its receptors. Based on a new study we propose that HHLA2 may represent a novel immunosuppressive mechanism within the tumor microenvironment and hence could be a target for cancer therapy. TMIGD2 may be another therapeutic target.

Original languageEnglish (US)
JournalOncoImmunology
Volume4
Issue number8
DOIs
StatePublished - Aug 3 2015

Fingerprint

Tumor Microenvironment
Immunosuppressive Agents
Therapeutics
Neoplasms
Immunoglobulin Domains

Keywords

  • angiogenesis
  • B7 family
  • CD28 family
  • HHLA2
  • immunosuppression
  • immunotherapy
  • ligand
  • receptor
  • TMIGD2
  • tumor microenvironment

ASJC Scopus subject areas

  • Immunology and Allergy
  • Oncology
  • Immunology

Cite this

HHLA2 and TMIGD2 : new immunotherapeutic targets of the B7 and CD28 families. / Janakiram, Murali; Chinai, Jordan M.; Zhao, Aimin; Sparano, Joseph A.; Zang, Xingxing.

In: OncoImmunology, Vol. 4, No. 8, 03.08.2015.

Research output: Contribution to journalArticle

@article{5cb3fca4673e4a3696eeecee51bb1376,
title = "HHLA2 and TMIGD2: new immunotherapeutic targets of the B7 and CD28 families",
abstract = "We and others recently discovered HHLA2 as a new B7 family member and transmembrane and immunoglobulin domain containing 2 (TMIGD2) as one of its receptors. Based on a new study we propose that HHLA2 may represent a novel immunosuppressive mechanism within the tumor microenvironment and hence could be a target for cancer therapy. TMIGD2 may be another therapeutic target.",
keywords = "angiogenesis, B7 family, CD28 family, HHLA2, immunosuppression, immunotherapy, ligand, receptor, TMIGD2, tumor microenvironment",
author = "Murali Janakiram and Chinai, {Jordan M.} and Aimin Zhao and Sparano, {Joseph A.} and Xingxing Zang",
year = "2015",
month = "8",
day = "3",
doi = "10.1080/2162402X.2015.1026534",
language = "English (US)",
volume = "4",
journal = "OncoImmunology",
issn = "2162-4011",
publisher = "Landes Bioscience",
number = "8",

}

TY - JOUR

T1 - HHLA2 and TMIGD2

T2 - new immunotherapeutic targets of the B7 and CD28 families

AU - Janakiram, Murali

AU - Chinai, Jordan M.

AU - Zhao, Aimin

AU - Sparano, Joseph A.

AU - Zang, Xingxing

PY - 2015/8/3

Y1 - 2015/8/3

N2 - We and others recently discovered HHLA2 as a new B7 family member and transmembrane and immunoglobulin domain containing 2 (TMIGD2) as one of its receptors. Based on a new study we propose that HHLA2 may represent a novel immunosuppressive mechanism within the tumor microenvironment and hence could be a target for cancer therapy. TMIGD2 may be another therapeutic target.

AB - We and others recently discovered HHLA2 as a new B7 family member and transmembrane and immunoglobulin domain containing 2 (TMIGD2) as one of its receptors. Based on a new study we propose that HHLA2 may represent a novel immunosuppressive mechanism within the tumor microenvironment and hence could be a target for cancer therapy. TMIGD2 may be another therapeutic target.

KW - angiogenesis

KW - B7 family

KW - CD28 family

KW - HHLA2

KW - immunosuppression

KW - immunotherapy

KW - ligand

KW - receptor

KW - TMIGD2

KW - tumor microenvironment

UR - http://www.scopus.com/inward/record.url?scp=84940569069&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84940569069&partnerID=8YFLogxK

U2 - 10.1080/2162402X.2015.1026534

DO - 10.1080/2162402X.2015.1026534

M3 - Article

AN - SCOPUS:84940569069

VL - 4

JO - OncoImmunology

JF - OncoImmunology

SN - 2162-4011

IS - 8

ER -